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Quest for the Holy Grail of
Tailored Antithrombotic Therapy?*
Germano Di Sciascio, MD,
Fabio Mangiacapra, MD
Rome, Italy
A large investigational effort has been made over the past 30
years in the attempt to identify the optimal antithrombotic
therapy for patients undergoing percutaneous coronary in-
tervention (PCI). One of the key messages consistently
arising from clinical trials is that the stronger the platelet
inhibition at the time of PCI, the lower the incidence of
thrombotic events following the procedure (1–4). The
periprocedural period is a vulnerable time frame during
which the patient’s prognosis is mainly delineated. An
adequate pre-PCI antiplatelet treatment is required not only
to prevent thrombotic complications immediately after the
procedure, but also to reduce recurrent ischemic events at
follow-up. This is particularly true for patients with acute
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coronary syndrome, where a more pronounced thrombotic
milieu is expected and strong platelet inhibition is even
more desirable. Using several platelet function tests, the
effect of platelet inhibitors, and of thienopyridine clopi-
dogrel in particular, has been extensively studied (5). A large
interindividual variability exists in platelet reactivity and
response to antiplatelet treatment, the latter being a multi-
factorial variable influenced by genetic, cellular, and clinical
factors (6). As a consequence, following pre-treatment with
the recommended 600-mg loading dose of clopidogrel, a
considerable proportion of patients undergo PCI with
inadequate levels of platelet inhibition (either too high or
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contents of this paper to disclose.too low). Whereas patients with increased response to
clopidogrel, and therefore low platelet reactivity, are ex-
posed to an increased risk of bleeding complications (7,8),
those with high platelet reactivity (HPR) present an in-
creased risk of ischemic complications (9–11). In patients
with non–ST-segment elevation myocardial infarction
(NSTEMI), HPR detected prior to PCI despite treatment
with clopidogrel has been associated with higher rates of
periprocedural myonecrosis (12) and 30-day ischemic events
including stent thrombosis (13).
In this issue of the Journal, Sibbing et al. (14) present the
results of a platelet substudy of ISAR-REACT 4 (Intra-
coronary Stenting and Antithrombotic Regimen: Rapid
Early Action for Coronary Treatment). In the main study,
the investigators compared the efficacy and safety of bivali-
rudin versus the combination of abciximab and unfraction-
ated heparin (UFH) in NSTEMI patients undergoing
urgent PCI after a 600-mg load of clopidogrel (15). They
found that at 30-day follow-up, both treatments were
associated with the same incidence of ischemic events
(death, recurrent myocardial infarction, target vessel revascu-
larization), whereas bivalirudin resulted in a significant re-
duction of major bleeding. The investigators conducted this
substudy to evaluate whether platelet reactivity, measured
after clopidogrel loading and before PCI with the Multi-
plate analyzer (Verum Diagnostika, Munich, Germany),
would influence outcomes regardless of the original ran-
domization allocation. Based on previous evidence (16),
HPR was defined as 468 arbitrary units (AU)  min,
whereas low platelet reactivity was defined as 188 AU 
min. The results showed that, while in the abciximab-UFH
arm efficacy was similar in patients with and without HPR
(9.4% vs. 6.7%; odds ratio [OR]: 1.4, 95% confidence interval
[CI]: 0.6 to 3.5, p 0.43), in the bivalirudin arm the incidence
of ischemic events was significantly higher in patients with
HPR (22.0% vs. 5.0%; OR: 5.4, 95% CI: 2.4 to 12.1, p 
0.0001), with a significant interaction between treatment arm
and platelet reactivity group (p for interaction  0.037).
Intuitively, this shows that a stronger platelet inhibition, such
as provided by abciximab, is necessary in NSTEMI patients
who still have HPR after pre-treatment with clopidogrel,
whereas bivalirudin alone appears to be inadequate in this
setting. Potential benefits from glycoprotein IIb/IIIa inhib-
itors in patients with persistent HPR despite clopidogrel
had been previously described by 2 relatively small random-
ized studies where additional, potent platelet inhibition
resulted in better periprocedural outcomes (17,18). The
present study further extends this evidence, showing that
the use of abciximab is able to mitigate the negative
influence of HPR by cutting the incidence of 30-day adverse
ischemic events (including large myocardial infarction) to
the level of patients without HPR. On the other hand, the
results of this study also suggest the lack of protective effect
by bivalirudin in patients with HPR, despite the demon-
strated antiplatelet effects of this drug. Bivalirudin has been
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July 31, 2012:378–80 Platelet Reactivity and PCIshown to suppress thrombin-dependent platelet activation
preventing cleavage of protease-activated receptor-1 (19), and
to further inhibit adenosine diphosphate–induced platelet
ggregation in patients pretreated with clopidogrel (20).
owever, to date no clear evidence of clinical benefit
orrelated to this antiplatelet effect of bivalirudin has
een provided. In contrast, according to the present
esults, bivalirudin might not be considered a reasonable
ption in NSTEMI patients with HPR at the time of
CI if given as the only antithrombotic drug on top of
lopidogrel. In fact, when considering only patients with
PR, those treated with bivalirudin presented an inci-
ence of ischemic events at 30 days as high as 22%, more
han double compared with that of patients receiving
bciximab plus UFH (9.4%).
Although largely underpowered to evaluate hemorrhagic
ndpoints, it is worth noting that the distribution of major
leeding reflected that observed in the main trial, with
igher incidence in patients receiving abciximab plus UFH
1.8% vs. 0.3%). Interestingly, in the latter group, all events
xcept 1 occurred in patients with low platelet reactivity, in
eeping with recent evidence that when platelet reactivity is
oo strongly inhibited, a significantly increased bleeding risk
rises (7,8), thereby lending further support to the concept
f a therapeutic window of platelet inhibition, which iden-
ifies patients with intermediate values of residual platelet
eactivity at lower risk for both ischemic and bleeding
omplications following PCI (16,21).
It is worth remembering that this is a post hoc analysis,
nvestigating only a minority of the entire population of
SAR-REACT 4; furthermore, the risk profile of the
atients included in the present substudy is different—and
ower—from that of the original population. Taking all of
his into account, and bearing in mind that they should be
onsidered with caution, the results of the present study
enerate an intriguing hypothesis enriching the scenario of
ailored antithrombotic strategies for patients undergoing
CI. Although recent trials have failed to demonstrate a
enefit from selecting antiplatelet treatment based on platelet
unction testing in low-risk patients, even when new more
otent P2Y12 inhibitors were used (22,23), a new paradigm is
ffered by ISAR-REACT 4 and its platelet substudy. In
articular, in NSTEMI patients with normal or low platelet
eactivity, bivalirudin could be used during PCI to achieve
imilar efficacy and a better safety profile compared with
bciximab plus UFH, whereas the latter should be reserved for
atients with residual HPR despite clopidogrel 600 mg in
rder to reduce recurrent ischemic events. This hypothesis, and
thers using newer antiplatelet drugs, need to be tested in
urther clinical trials. And the quest can go on.
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